<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        23-584-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ODECON 150 mg Capsule
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FLUCONAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        150
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        15.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NEOPHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NEOPHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NEOPHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J02AC01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Odecon Capsules 150 mg is one of a group of medicines called &ldquo;antifungals&rdquo;. The<br />active substance is fluconazole.<br />Odecon Capsules 150 mg are used to treat infections caused by fungi and may also be<br />used to stop you from getting a candidal infection. The most common cause of fungal<br />infections is a yeast called Candida.</p><p>Adults<br />You might be given this medicine by your doctor to treat the following types of fungal<br />infections:<br />&bull; Cryptococcal meningitis &ndash; a fungal infection in the brain<br />&bull; Coccidioidomycosis &ndash; a disease of the bronchopulmonary system<br />&bull; Infections caused by Candida and found in the blood stream, body organs (e.g.<br />heart, lungs) or urinary tract<br />&bull; Mucosal thrush - infection affecting the lining of the mouth, throat and denture<br />sore mouth<br />&bull; Genital thrush &ndash; infection of the vagina or penis<br />&bull; Skin infections - e.g. athlete&rsquo;s foot, ringworm, jock itch, nail infection<br />You might also be given Odecon Capsules 150 mg to:<br />&bull; stop cryptococcal meningitis from coming back<br />&bull; stop mucosal thrush from coming back<br />&bull; reduce recurrence of vaginal thrush<br />&bull; stop you from getting an infection caused by Candida (if your immune system is<br />weak and not working properly)<br />Children and adolescents (0 to 17 years old)<br />You might be given this medicine by your doctor to treat the following types of fungal<br />infections:<br />&bull; Mucosal thrush - infection affecting the lining of the mouth, throat<br />&bull; Infections caused by Candida and found in the blood stream, body organs (e.g.<br />heart, lungs) or urinary tract<br />&bull; Cryptococcal meningitis &ndash; a fungal infection in the brain<br />You might also be given Odecon Capsules 150 mg to:<br />&bull; stop you from getting an infection caused by Candida (if your immune system is<br />weak and not working properly).<br />&bull; stop cryptococcal meningitis from coming back</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>2. What you need to know before you take Odecon Capsules 150 mg<br />Do not take Odecon Capsules 150 mg<br />&bull; if you are allergic to fluconazole, to other medicines you have taken to treat fungal<br />infections or to any of the other ingredients of this medicine (listed in section 6).<br />The symptoms may include itching, reddening of the skin or difficulty in breathing<br />&bull; if you are taking astemizole, terfenadine (antihistamine medicines for allergies)<br />&bull; if you are taking cisapride (used for stomach upsets)<br />&bull; if you are taking pimozide (used for treating mental illness)<br />&bull; if you are taking quinidine (used for treating heart arrhythmia)<br />&bull; if you are taking erythromycin (an antibiotic for treating infections)<br />Warnings and precautions<br />Talk to your doctor or pharmacist before taking Odecon Capsules 150 mg<br />&bull; if you have liver or kidney problems<br />&bull; if you suffer from heart disease, including heart rhythm problems<br />&bull; if you have abnormal levels of potassium, calcium or magnesium in your blood<br />&bull; if you develop severe skin reactions (itching, reddening of the skin or difficulty in<br />breathing)<br />&bull; if you develop signs of &lsquo;adrenal insufficiency&rsquo; where the adrenal glands do not<br />produce adequate amounts of certain steroid hormones such as cortisol (chronic,<br />or long lasting fatigue, muscle weakness, loss of appetite, weight loss, abdominal<br />pain)</p><p>Other medicines and Odecon Capsules 150 mg<br />Tell your doctor immediately if you are taking astemizole, terfenadine (an antihistamine<br />for treating allergies) or cisapride (used for stomach upsets) or pimozide (used for<br />treating mental illness) or quinidine (used for treating heart arrhythmia) or erythromycin<br />(an antibiotic for treating infections) as these should not be taken with Odecon<br />Capsules 150 mg (see section: &ldquo;Do not take Odecon Capsules 150 mg if you&rdquo;).<br />There are some medicines that may interact with Odecon Capsules 150 mg. Make<br />sure your doctor knows if you are taking any of the following medicines:<br />&bull; rifampicin or rifabutin (antibiotics for infections)<br />&bull; alfentanil, fentanyl (used as anaesthetic)<br />&bull; amitriptyline, nortriptyline (used as anti-depressant)<br />&bull; amphotericin B, voriconazole (anti-fungal)<br />&bull; medicines that thin the blood to prevent blood clots (warfarin or similar medicines)<br />&bull; benzodiazepines (midazolam, triazolam or similar medicines) used to help you<br />sleep or for anxiety<br />&bull; carbamazepine, phenytoin (used for treating fits)<br />&bull; nifedipine, isradipine, amlodipine, verapamil, felodipine and losartan (for<br />hypertension - high blood pressure)<br />&bull; olaparib (used for treating ovarian cancer)<br />&bull; ciclosporin, everolimus, sirolimus or tacrolimus (to prevent transplant rejection)<br />&bull; cyclosphosphamide, vinca alkaloids (vincristine, vinblastine or similar medicines)<br />used for treating cancer<br />&bull; halofantrine (used for treating malaria)<br />&bull; statins (atorvastatin, simvastatin and fluvastatin or similar medicines) used for<br />reducing high cholesterol levels<br />&bull; methadone (used for pain)<br />&bull; celecoxib, flurbiprofen, naproxen, ibuprofen, lornoxicam, meloxicam, diclofenac<br />(Non-Steroidal Anti-Inflammatory Drugs (NSAID))<br />&bull; oral contraceptives<br />&bull; prednisone (steroid)<br />&bull; zidovudine, also known as AZT; saquinavir (used in HIV-infected patients)<br />&bull; medicines for diabetes such as chlorpropamide, glibenclamide, glipizide or<br />tolbutamide<br />&bull; theophylline (used to control asthma)<br />&bull; tofacitinib (used for treating rheumatoid arthritis)<br />&bull; vitamin A (nutritional supplement)<br />&bull; ivacaftor (used for treating cystic fibrosis)<br />&bull; amiodarone (used for treating uneven heartbeats &lsquo;arrhythmias&rsquo;)<br />&bull; hydrochlorothiazide (a diuretic)<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any<br />other medicines.</p><p>Odecon Capsules 150 mg with food and drink<br />You can take your medicine with or without a meal.<br />Pregnancy, breast-feeding and fertility<br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to<br />have a baby, ask your doctor or pharmacist for advice before taking this medicine.<br />You should not take Odecon Capsules 150 mg while you are pregnant unless your<br />doctor has told you to.<br />You can continue breast-feeding after taking a single dose of 150 mg Odecon Capsule.<br />You should not breast-feed if you are taking a repeated dose of Odecon Capsules<br />150 mg.<br />Driving and using machines<br />When driving vehicles or using machines, it should be taken into account that<br />occasionally dizziness or fits may occur.<br />Odecon Capsules 150 mg contains lactose (milk sugar)<br />This medicine contains a small amount of lactose (milk sugar). If you have been told by<br />your doctor that you have an intolerance to some sugars, please contact your doctor<br />before taking this medicine&nbsp;<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take your medicine exactly as your doctor has told you. You should check with<br />your doctor or pharmacist if you are not sure.<br />Swallow the capsule whole with a glass of water. It is best to take your capsules at<br />the same time each day.<br />The recommended doses of this medicine for different infections are below:</p><p>Adults<br />Condition Dose<br />To treat cryptococcal meningitis 400 mg on the first day then 200 mg to<br />400 mg once daily for 6 to 8 weeks or<br />longer if needed. Sometimes doses are<br />increased up to 800 mg<br />To stop cryptococcal meningitis<br />from coming back<br />200 mg once daily until you are told<br />to stop<br />To treat coccidioidomycosis 200 mg to 400 mg once daily from 11<br />months for up to 24 months or longer<br />if needed. Sometimes doses are<br />increased up to 800 mg<br />To treat internal fungal infections<br />caused by Candida<br />800 mg on the first day then 400 mg<br />once daily until you are told to stop<br />To treat mucosal infections<br />affecting the lining of mouth,<br />throat and denture sore mouth<br />200 mg to 400 mg on the first day<br />then 100 mg to 200 mg until you are<br />told to stop<br />To treat mucosal thrush &ndash; dose<br />depends on where the infection<br />is located<br />50 mg to 400 mg once daily for 7 to 30<br />days until you are told to stop<br />To stop mucosal infections<br />affecting the lining of mouth,<br />throat from coming back<br />100 mg to 200 mg once daily, or 200<br />mg 3 times a week, while you are at<br />risk of getting an infection<br />To treat genital thrush 150 mg as a single dose<br />To reduce recurrence of vaginal<br />thrush<br />150 mg every third day for a total of 3<br />doses (day 1, 4 and 7) and then once a<br />week for 6 months while you are at risk<br />of getting an infection<br />To treat fungal skin and nail<br />infections<br />Depending on the site of the infection<br />50 mg once daily, 150 mg once<br />weekly, 300 to 400 mg once weekly for<br />1 to 4 weeks (Athlete&rsquo;s foot may be up<br />to 6 weeks, for nail infection treatment<br />until infected nail is replaced</p><p>To stop you from getting an<br />infection caused by Candida<br />(if your immune system is weak<br />and not working properly)<br />200 mg to 400 mg once daily while<br />you are at risk of getting an infection<br />Adolescents from 12 to 17 years old<br />Follow the dose prescribed by your doctor (either adults or children posology).<br />Children to 11 years old<br />The maximum dose for children is 400 mg daily.<br />The dose will be based on the child&rsquo;s weight in kilograms</p><p>Condition Daily dose<br />Mucosal thrush and throat infections<br />caused by Candida &ndash; dose and<br />duration depends on the severity<br />of the infection and on where the<br />infection is located<br />3 mg per kg of body weight once<br />daily (6 mg per kg of body weight<br />might be given on the first day)<br />Cryptococcal meningitis or internal<br />fungal infections caused by Candida<br />6 mg to 12 mg per kg of body<br />weight once daily<br />To stop cryptococcal meningitis from<br />coming back<br />6 mg per kg of body weight once<br />daily<br />To stop children from getting an<br />infection caused by Candida (if<br />their immune system is not working<br />properly)<br />3 mg to 12 mg per kg of body<br />weight once daily</p><p>Use in children 0 to 4 weeks of age<br />Use in children of 3 to 4 weeks of age:<br />The same dose as above but given once every 2 days. The maximum dose is 12 mg<br />per kg of body weight every 48 hours.<br />Use in children less than 2 weeks old:<br />The same dose as above but given once every 3 days. The maximum dose is 12 mg<br />per kg of body weight every 72 hours.<br />Elderly<br />The usual adult dose should be given unless you have kidney problems.<br />Patients with kidney problems<br />Your doctor may change your dose, depending on your kidney function.<br />If you take more Odecon Capsules 150 mg than you should<br />Taking too many capsules at once may make you unwell. Contact your doctor or your<br />nearest hospital casualty department at once. The symptoms of a possible overdose<br />may include hearing, seeing, feeling and thinking things that are not real (hallucination<br />and paranoid behaviour). Symptomatic treatment (with supportive measures and<br />gastric lavage if necessary) may be adequate.<br />If you forget to take Odecon Capsules 150 mg<br />Do not take a double dose to make up for a forgotten dose. If you forget to take a<br />dose, take it as soon as you remember. If it is almost time for your next dose, do not<br />take the dose that you missed.<br />If you have any further questions on the use of this medicine, ask your doctor or<br />pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>4. Possible side effects<br />Like all medicines, this medicine can cause side effects, although not everybody gets<br />them.<br />A few people develop allergic reactions although serious allergic reactions are rare. If<br />you get any side effects, talk to your doctor or pharmacist. This includes any possible<br />side effects not listed in this leaflet. If you get any of the following symptoms, tell your<br />doctor immediately.<br />&bull; sudden wheezing, difficulty in breathing or tightness in the chest<br />&bull; swelling of eyelids, face or lips<br />&bull; itching all over the body, reddening of the skin or itchy red spots<br />&bull; skin rash<br />&bull; severe skin reactions such as a rash that causes blistering (this can affect the<br />mouth and tongue).<br />Odecon Capsules 150 mg may affect your liver. The signs of liver problems include:<br />&bull; tiredness<br />&bull; loss of appetite<br />&bull; vomiting<br />&bull; yellowing of your skin or the whites of your eyes (jaundice)<br />If any of these happen, stop taking Odecon Capsules 150 mg and tell your doctor<br />immediately.<br />Other side effects:<br />Additionally, if any of the following side effects gets serious, or if you notice any side<br />effects not listed in this leaflet, please tell your doctor or pharmacist.<br />Common side effects (may affect up to 1 in 10 people) are:<br />&bull; headache<br />&bull; stomach discomfort, diarrhoea, feeling sick, vomiting<br />&bull; increases in blood tests of liver function<br />&bull; rash<br />Uncommon side effects (may affect up to 1 in 100 people) are:<br />&bull; reduction in red blood cells which can make skin pale and cause weakness or<br />breathlessness<br />&bull; decreased appetite<br />&bull; inability to sleep, feeling drowsy<br />&bull; fit, dizziness, sensation of spinning, tingling, pricking or numbness, changes in<br />sense of taste<br />&bull; constipation, difficult digestion, wind, dry mouth<br />&bull; muscle pain<br />&bull; liver damage and yellowing of the skin and eyes (jaundice)<br />&bull; wheals, blistering (hives), itching, increased sweating<br />&bull; tiredness, general feeling of being unwell, fever<br />Rare side effects (may affect up to 1 in 1,000 people) are:<br />&bull; lower than normal white blood cells that help defend against infections and blood<br />cells that help to stop bleeding<br />&bull; red or purple discoloration of the skin which may be caused by low platelet count,<br />other blood cell changes<br />&bull; blood chemistry changes (high blood levels of cholesterol, fats)<br />&bull; low blood potassium<br />&bull; shaking<br />&bull; abnormal electrocardiogram (ECG), change in heart rate or rhythm<br />&bull; liver failure<br />&bull; allergic reactions (sometimes severe), including widespread blistering rash and<br />skin peeling, severe skin reactions, swelling of the lips or face<br />&bull; hair loss&nbsp;</p><p>Frequency not known, but may occur (cannot be estimated from the available<br />data):<br />&bull; hypersensitivity reaction with skin rash, fever, swollen glands, increase in a type<br />of white blood cell (eosinophilia) and inflammation of internal organs (liver, lungs,<br />heart, kidneys and large intestine) (Drug Reaction or rash with Eosinophilia and<br />Systemic Symptoms (DRESS))<br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any<br />possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>5. How to store Odecon Capsules 150 mg<br />&bull; Keep this medicine out of the sight and reach of children.<br />&bull; Do not use this medicine after the expiry date (EXP) which is stated on the blister<br />strip and the carton. The expiry date refers to the last day of that month.<br />&bull; Store below 30&deg;C.<br />&bull; Do not throw away any medicines via waste-water or household waste. Ask your<br />pharmacist how to throw away medicines you no longer use. These measures will<br />help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Odecon Capsules 150 mg contain<br />&bull; The active substance is fluconazole.<br />&bull; Each hard gelatin capsule contains Fluconazole 150 mg.<br />&bull; The other ingredients are Lactose, Maize Starch, Sodium Lauryl Sulphate, Colloidal<br />Anhydrous Silica, Purified Talc and Hard Gelatin Capsule Shells, Size &lsquo;0&rsquo;.<br />Capsule Shell Composition: Gelatin, Indigo Carmine (FD&amp;C Blue 2), Titanium Dioxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Size “0” hard gelatin capsules with turquoise coloured cap imprinted with ‘FL150’
in black colour and turquoise coloured body, filled with white to off-white granular
powder free from visible extraneous matter.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Neopharma,<br />Plot A-1 89-95, ICAD, Mussafah,<br />P.O. Box 72900, Abu Dhabi, UAE</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                03/2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ما هي كبسولات أوديكون 150 ملجم، وما هي دواعي استعمالها<br />كبسولات أوديكون 150 ملجم تنتمي إلى مجموعة من الأدوية تُعرف باسم &ldquo;مضادات الفطريات&rdquo;.<br />المادة الفعالة هي الفلوكونازول.<br />تُستخدم كبسولات أوديكون 150 ملجم في علاج العدوى التي تسببها الفطريات وربما تُستخدم<br />أيضاً في وقايتك من الإصابة بعدوى المبيضات. يعود أكثر أسباب العدوى الفطرية شيوعاً إلى نوع من<br />الخمائر تعرف باسم المبيضات.<br />البالغون<br />ربما يصف لك طبيبك هذا الدواء لعلاج الأنواع التالية من العدوى الفطرية:<br />&bull;التهاب السحايا بالمستخفيات - عدوى فطرية في المخ<br />&bull;الفُطار الكرواني - مرض يصيب الجهاز القصبي الرئوي<br />&bull;العدوى التي تسببها المبيضات وتوجد في مجرى الدم، أو أعضاء الجسم )مثل القلب والرئتين(<br />أو الجهاز البولي<br />&bull;السلاق المخاطي - عدوى تصيب بطانة الفم والحلق وتسبب احتقاناً في الفم من الداخل عند<br />موضع الأسنان<br />&bull;السلاق التناسلي - عدوى المهبل أو القضيب<br />&bull;الأمراض الجلدية - مثل القدم الرياضية والقوباء الحلقية وحكة جوك وعدوى الأظافر<br />ربما يُوصف لك كبسولات أوديكون 150 ملجم في الحالات التالية:<br />&bull;الوقاية من معاودة الإصابة بالتهاب السحايا بالمستخفيات<br />&bull;الوقاية من معاودة الإصابة بمرض السلاق المخاطي<br />&bull;تقليل فرصة تكرار العدوى بمرض السلاق المهبلي<br />&bull;الوقاية من الإصابة بعدوى المبيضات )في حال ضعف جهازك المناعي وعدم أدائه بكفاءة(<br />الأطفال والمراهقون )الذين يبلغون 17 عاماً فأقل(<br />ربما يوصف لك طبيبك هذا الدواء لعلاج الأنواع التالية من العدوى الفطرية:<br />&bull;السلاق المخاطي - عدوى تصيب بطانة الفم والحلق<br />&bull;العدوى التي تسببها المبيضات وتوجد في مجرى الدم أو أعضاء الجسم )مثل القلب والرئتين(<br />أو الجهاز البولي<br />&bull;التهاب السحايا بالمستخفيات - عدوى فطرية في المخ<br />ربما يوصف لك كبسولات أوديكون 150 ملجم في الحالات التالية:<br />&bull;الوقاية من الإصابة بعدوى المبيضات )في حال ضعف جهازك المناعي وعدم أدائه بكفاءة(.<br />&bull;الوقاية من معاودة الإصابة بالتهاب السحايا بالمستخفيات<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تناول كبسولات أوديكون 150 ملجم<br />&bull;إذا كنت مصاباً بحساسية من مادة الفلوكونازول أو من أي أدوية أخرى تناولتها من قبل لعلاج<br />العدوى الفطرية أو أي مكونات أخرى في هذا الدواء )واردة في القسم 6(. قد تتضمن أعراض<br />الحساسية حكة أو احمرار الجلد أو صعوبة في التنفس<br />&bull;إذا كنت تتناول أستيميزول أو تيرفينادين )أدوية مضادة للهيستامين لعلاج الحساسية(<br />&bull;إذا كنت تتناول سيسابريد )يُستخدم في علاج اضطرابات المعدة(<br />&bull;إذا كنت تتناول بيموزيد )يُستخدم في علاج الأمراض العقلية(<br />&bull;إذا كنت تتناول كينيدين )يُستخدم في علاج اضطرابات نظم ضربات القلب(<br />&bull;إذا كنت تتناول إريثروميسين )مضاد حيوي يستخدم في علاج العدوى(الاحتياطات والتحذيرات<br />تحدث إلى طبيبك أو الصيدلي قبل تناول كبسولات أوديكون 150 ملجم<br />&bull;إذا كنت تعاني من مشكلات في الكبد أو الكُلى<br />&bull;إذا كنت تعاني من مرض في القلب، بما في ذلك مشكلات عدم انتظام معدل ضربات القلب<br />&bull;إذا كانت مستويات البوتاسيوم أو الكالسيوم أو الماغنيسيوم في دمك غير طبيعية<br />&bull;إذا كنت تعاني من تفاعلات جلدية حادة )حكة أو احمرار الجلد أو صعوبة في التنفس(<br />&bull;إذا ظهر عليك علامات مرض &ldquo;قصور الكظرية&rdquo; حيث لا تفرز الغدد الكظرية كميات كافية من<br />الهرمونات الستيرويدية مثل الكورتيزول )إجهاد مزمن أو طويل المدة ووهن العضلات فقدان<br />الشهية وخسارة الوزن وألم في البطن(<br />التفاعلات مع الأدوية الأخرى<br />أخبر طبيبك على الفور إذا كنت تتناول أستيميزول أو تيرفينادين )أدوية مضادة للهيستامين لعلاج<br />الحساسية( أو سيسابريد )يُستخدم في علاج اضطرابات المعدة( أو بيموزيد )يُستخدم في علاج<br />الأمراض العقلية( أو كينيدين )يُستخدم في علاج اضطرابات نظم ضربات القلب( أو إريثروميسين<br />)مضاد حيوي لعلاج العدوى(؛ إذ يجب ألا تتناول مثل هذه الأدوية في نفس الوقت مع كبسولات أوديكون<br />150 ملجم )انظر قسم &ldquo;لا تناول كبسولات أوديكون 150 ملجم&rdquo;(.<br />هناك بعض الأدوية التي ربما تتفاعل مع كبسولات أوديكون 150 ملجم.</p><p>تأكد من استشارة طبيبك إذا كنت تتناول أياً من الأدوية التالية:<br />&bull;ريفامبيسين أو ريفابوتين )مضادات حيوية لعلاج العدوى(<br />&bull;ألفنتانيل فنتانيل )تُستخدم كمخدر(<br />&bull;أميتريبتيلين ونورتريبتالين )تُستخدم كمضادات للاكتئاب(<br />&bull;أمفوتيريسين ب وفوريكونازول )أدوية مضادة للفطريات(<br />&bull;الأدوية التي تسبب سيولة الدم للوقاية من تكون جلطات الدم )وارفارين أو أدوية مشابهة(<br />&bull;البنزوديازيبينات )ميدازولام أو تريازولام أو أدوية مشابهة( التي تساعد في النوم وتُستخدم في<br />علاج التوتر والقلق<br />&bull;كاربامازيبين، فينيتوين )يُستخدم في علاج النوبات المرضية(<br />&bull;نيفيديبين، اسراديبين، أملوديبين، فيراباميل، فيلوديبين، لوسارتان )لعلاج ضغط الدم المرتفع(<br />&bull;سيكلوسبورين أو ايفيروليموس أو سيروليموس أو تاكروليموس )للوقاية من رفض الأعضاء<br />المزروعة(<br />&bull;أولاباريب يستخدم لعلاج سرطان المبيض<br />&bull;سيكلوفوسفاميد، قلويدات الفينكا )فينكريستين أو فينبلاستين أو أدوية مشابهة( تُستخدم<br />في علاج السرطان<br />&bull;هالوفانترين )يُستخدم في علاج الملاريا(<br />&bull;الستاتينات )أتورفاستاتين وسيمفاستاتين وفلوفاستاتين أو أدوية مشابهة( تُستخدم في خفض<br />مستويات الكوليسترول المرتفعة<br />&bull;ميثادون )يُستخدم لتسكين الألم(<br />&bull;سيليكوكسيب وفلوربيبروفين ونابروكسين وآيبوبروفين ولورنوكسيكام، وميلوكسيكام،<br />))NSAID&rsquo;s( وديكلوفيناك )مضادات الالتهاب غير الاستيرويدية<br />&bull;وسائل منع الحمل التي تؤخذ عن طريق الفم<br />&bull;بريدنيزون )ستيرويد(<br />ساكوينافير )يستخدمه المرضى المصابون بعدوى فيروس ؛AZT &bull;زيدوفودين، ويُعرف أيضاً باسم<br />العوز المناعي البشري(<br />&bull;الأدوية المتخصصة في علاج داء السكري مثل كلوربروباميد أو جليبنكلاميد أو غليبيزيد أو<br />تولبوتاميد<br />&bull;ثيوفيلين )يستعمل في علاج الربو.<br />&bull;توفاسيتينيب )يستخدم لعلاج التهاب المفاصل الروماتويدي(<br />&bull;فيتامين أ )مكمل غذائي(<br />&bull;ايفاكافتور )يُستخدم في علاج التليف الكيسي(<br />&bull;أميودارون )يُستخدم في علاج عدم انتظام ضربات القلب &ldquo;اضطراب نظم ضربات القلب&rdquo;(<br />&bull;هيدروكلوروثيازايد )مدر للبول(<br />أخبر الطبيب أو الصيدلي إذا كنت تتناول أدوية أخرى أو تناولتها مؤخراً أو من المحتمل أن تتناولها.<br />كبسولات أوديكون 150 ملجم مع الطعام والشراب<br />يمكنك تناول دوائك مع الطعام أو بدونه.<br />الحمل والرضاعة الطبيعية والخصوبة<br />إذا كنت حاملاً أو ترضعين أو تعتقدين أنك حامل أو تخططين للحمل فاطلبي النصيحة من الطبيب<br />أو الصيدلي قبل تناول هذا الدواء.<br />يجب ألا تتناولي كبسولات أوديكون 150 ملجم طوال فترة الحمل ما لم يخبرك طبيبك بخلاف ذلك.<br />يمكنك مواصلة الرضاعة الطبيعية بعد تناول جرعة واحدة من كبسولات أوديكون 150 ملجم.<br />يجب ألا ترضعي طفلك إذا كنتِ تتناولين جرعة متكررة من كبسولات أوديكون 150 ملجم</p><p>عند قيادة المركبات أو استخدام الآلات، يجب الأخذ في الاعتبار أنه يمكن أن تُصاب بالدوار أو النوبات<br />المرضية.<br />تحتوي كبسولات أوديكون 150 ملجم على اللاكتوز )سكر الحليب(<br />يحتوي هذا الدواء على مقدار صغير من اللاكتوز )سكر الحليب(. إذا أخبرك طبيبك أنك تعاني من<br />حساسية من بعض أنواع السكر فاستشر طبيبك قبل تناول هذا الدواء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول هذا الدواء دائماً حسب وصف الطبيب. يجب استشارة الطبيب أو الصيدلي إذا لم تكن متأكداً.<br />ابتلع الكبسولة بالكامل مع كوب من الماء. حاول تناول جرعتك اليومية من الكبسولات في نفس<br />الوقت من كل يوم.<br />فيما يلي الجرعات الموصى بها من هذا الدواء لعلاج العدوى المختلفة:<br />البالغون<br />الحالة المرضية الجرعة<br />لعلاج التهاب السحايا<br />بالمستخفيات<br />400 ملجم في اليوم الأول ثم جرعة تتراوح بين 200<br />ملجم و 400 ملجم مرة واحدة يومياً لمدة تتراوح بين<br />6 و 8 أسابيع أو أكثر عند اللزوم. أحياناً تزيد الجرعات<br />لتصل إلى 800 ملجم<br />للوقاية من معاودة الإصابة<br />بالتهاب السحايا بالمستخفيات<br />200 ملجم مرة واحدة يومياً حتى يخبرك طبيبك<br />بأن تتوقف عن تناولها<br />لعلاج الفُطار الكرواني جرعة تتراوح بيم 200 ملجم و 400 ملجم مرة<br />واحدة يومياً لمدة تبدأ من 11 شهراً وحتى 24 شهراً<br />أو أكثر من ذلك عند اللزوم. أحياناً تزيد الجرعات<br />لتصل إلى 800 ملجم<br />لعلاج العدوى الفطرية الداخلية<br />التي تسببها المبيضات<br />800 ملجم في اليوم الأول ثم 400 ملجم مرة واحدة<br />يومياً حتى يخبرك طبيبك بأن تتوقف عن تناولها<br />لعلاج عدوى الأغشية المخاطية<br />التي تصيب بطانة الفم والحلق<br />وتسبب احتقاناً في الفم من<br />الداخل عند موضع الأسنان<br />جرعة تتراوح بين 200 ملجم و 400 ملجم في اليوم<br />الأول ثم تناول جرعة تتراوح بين 100 ملجم و 200<br />ملجم حتى يخبرك طبيبك بأن تتوقف عن تناولها.<br />لعلاج السلاق المخاطي - تعتمد<br />الجرعة على مكان الإصابة بالعدوى<br />جرعة تتراوح بين 50 ملجم إلى 400 ملجم مرة<br />واحدة يومياً لمدة تتراوح بين 7 و 30 يوماً حتى يخبرك<br />طبيبك بأن تتوقف عن تناولها.<br />لمنع عدوى الأغشية المخاطية التي<br />تصيب بطانة الفم والحلق من<br />العوده مجددا<br />جرعة تتراوح بين 100 ملجم و 200 ملجم مرة واحدة<br />يومياً، أو 200 ملجم 3 مرات أسبوعياً، عندما تكون<br />معرضاً لخطر الإصابة بعدوى.<br />لعلاج السُّلاق التناسلي 150 ملجم كجرعة واحدة<br />لتقليل فرصة تكرار الإصابة بمرض<br />السلاق المهبلي<br />150 ملجم كل ثلاثة أيام لعدد من الجرعات يصل<br />في مجمله إلى 3 جرعات )اليوم الأول واليوم الرابع<br />واليوم السابع( ثم جرعة واحدة أسبوعياً لمدة 6<br />أشهر عندما تكون معرضاً لخطر الإصابة بعدوى.<br />لعلاج الجلد والأظافر المصابة<br />بعدوى فطرية<br />حسب مكان العدوى تبلغ الجرعة 50 ملجم مرة<br />واحدة يومياً، 150 ملجم مرة واحدة أسبوعياً،<br />وجرعة تتراوح بين 300 و 400 ملجم مرة واحدة<br />أسبوعياً لمدة تتراوح بين 1 و 4 أسابيع )لعلاج القدم<br />الرياضي تمتد الجرعة حتى 6 أسابيع، ولعلاج عدوى<br />الأظافر حتى يُستبدل الظفر المصاب بالكامل</p><p>المبيضات )إذا كان جهاز المناعة<br />لديك ضعيفًا ولا يعمل بشكل<br />صحيح(<br />200 ملجم إلى 400 ملجم مرة واحدة يوميًا أثناء<br />تعرضك لخطر الإصابة<br />المراهقون الذين تتراوح أعمارهم بين 12 و 17 عاماً<br />اتبع الجرعة التي يصفها لها طبيبك )تحديد الجرعات للبالغين أو الأطفال(<br />الأطفال الذين يبلغون 11 عاماً فأقل<br />تبلغ الجرعة القصوى للأطفال 400 ملجم يومياً.<br />تُدد الجرعة حسب وزن الطفل بالكيلوجرام.<br />الحالة المرضية الجرعة اليومية<br />فى حال مرض السلاق اﻟﻤﺨاطي<br />وعدوى الحلق التي تسببها<br />المبيضات - تعتمد الجرعةومدة<br />تناولها على شدة العدوى<br />ومكانها في الجسم.<br />3 ملجم لكل كيلوجرام من وزن الجسم مره واحده<br />يوميا)قد تُعطى جرعة مقدارها 6 ملجم لكل<br />كيلوجرام من وزن الجسم في اليوم الأول(<br />التهاب السحايا بالمستخفيات أو<br />العدوى الفطرية الداخلية بسبب<br />المبيضات<br />6 ملجم إلى 12 ملجم لكل كيلوجرام من وزن<br />الجسم مره واحده يوميا<br />لمنع التهاب السحايا<br />بالمستخفيات من العود ه مجددا<br />6 ملجم لكل كيلوجرام من وزن الجسم مره<br />واحده يوميا<br />لوقاية الأطفال من الإصابة بعدوى<br />المبيضات )في حال عدم أداء<br />جهازهم المناعي بكفاءه(<br />3 ملجم إلى 12 ملجم لكل كيلوجرام من وزن<br />الجسم مره واحده يوميا<br />الاستخدام من قبل الأطفال الذين يبلغون 4 أسابيع فأقل<br />الاستخدام من قبل الأطفال الذين تتراوح أعمارهم بين 3 و 4 أسابيع:<br />نفس الجرعة المذكورة أعلاه، ولكن تؤخذ مرة واحدة كل يومين. تبلغ الجرعة القصوى 12 ملجم لكل<br />كيلوجرام من وزن الجسم كل 48 ساعة.<br />الاستخدام من قبل الأطفال الذين تقل أعمارهم عن أسبوعين:<br />نفس الجرعة المذكورة أعلاه، ولكن تؤخذ مرة واحدة كل ثلاثة أيام. تبلغ الجرعة القصوى 12 ملجم لكل<br />كيلوجرام من وزن الجسم كل 72 ساعة.<br />الأطفال الأكبر سناً<br />يجب تناول الجرعة المعتادة الخاصة بالبالغين إلا إذا كانوا يعانون من مشكلات في الكُلى.<br />المرضى المصابون بمشكلات في الكُلى<br />قد يغير طبيبك الجرعة بناء على مستوى أداء وظائف الكُلى.</p><p>إذا تجاوزت الجرعة الموصوفة من كبسولات أوديكون 150 ملجم<br />قد يؤدي تناول جرعة زائدة من الكبسولات مرة واحدة إلى الشعور بالإعياء؛ لذا اتصل بطبيبك أو<br />توجه إلى قسم الإصابات في أقرب مستشفى على الفور. قد تشمل الأعراض المحتملة للجرعة الزائدة<br />سماع أشياء غير حقيقية ورؤيتها والشعور بها والتفكير فيها )هلوسة وسلوك ارتيابي(. قد تكون<br />معالجة الأعراض )من خلال اتخاذ الإجراءات الداعمة وغسيل المعدة عند الضرورة( كافية.<br />إذا نسيت تناول كبسولات أوديكون 150 ملجم<br />لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية. إذا نسيت تناول الجرعة فتناولها بمجرد تذكرك. إذا<br />اقترب موعد تناول الجرعة التالية فلا تتناول الجرعة الفائتة.<br />إذا كان لديك أي أسئلة أخرى عن طريقة استخدام هذا الدواء فسل الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>يظهر لدى القليل من الأشخاص تفاعلات حساسية بالرغم من أن تفاعلات الحساسية الحادة أمر نادر<br />الحدوث. إذا ظهر عليك أي أعراض جانبية فأخبر الطبيب أو الصيدلي. ويشمل هذا أي أعراض جانبية<br />محتملة غير واردة في هذه النشرة. إذا ظهر عليك أي من الأعراض التالية فأخبر طبيبك على الفور.<br />&bull;صفير مفاجئ عند التنفس أو صعوبة في التنفس أو ضيق في الصدر<br />&bull;تورم الجفون أو الوجه أو الشفاه<br />&bull;حكة في جميع أجزاء الجسم أو احمرار الجلد أو بقع حمراء مثيرة للحكة<br />&bull;الطفح الجلدي<br />&bull;تفاعلات حادة في الجلد مثل الطفح الجلدي الذي يسبب بثوراً متقيحة )ويمكن أن تصيب الفم<br />واللسان(.<br />قد تؤثر كبسولات أوديكون 150 ملجم في الكبد. تشمل علامات حدوث مشكلات في الكبد:<br />&bull;الشعور بالتعب<br />&bull;فقدان الشهية<br />&bull;القيء<br />&bull;اصفرار الجلد وبياض العينين )الصفراء(<br />إذا حدث أي من الأعراض السابقة فتوقف عن تناول كبسولات أوديكون 150 ملجم وأخبر طبيبك<br />على الفور.<br />الأعراض الجانبية الأخرى:<br />فضلاً عن ذلك، إذا تطور أي من الأعراض الجانبية التالية إلى درجة خطيرة أو إذا لاحظت حدوث أي<br />أعراض جانبية غير مدرجة بهذه النشرة فأخبر الطبيب أو الصيدلي.<br />الأعراض الجانبية الشائعة )قد تصيب شخصاً واحداً من كل 10 أشخاص(:<br />&bull;صداع<br />&bull;اضطراب في المعدة وإسهال وشعور بالغثيان وقيء<br />&bull;زيادة في معدلات نتائج اختبارات الدم الخاصة بوظائف الكبد<br />&bull;طفح جلدي<br />الأعراض الجانبية غير الشائعة )قد تصيب شخصاً واحداً من كل 100 شخص(:<br />&bull;قلة عدد خلايا الدم الحمراء والتي قد تجعل الجلد شاحباً، كما أنها تتسبب في حدوث ضعف أو<br />ضيق في التنفس<br />&bull;فقدان الشهية<br />&bull;عدم القدرة على النوم والشعور بالنعاس<br />&bull;نوبات مرضية ودوخة والإحساس بالدوار وشعور بالوخز أو الدغدغة أو التخدير وتغيرات في<br />حاسة التذوق<br />&bull;إمساك وعسر هضم وريح وجفاف الفم<br />&bull;ألم في العضلات<br />&bull;تلف في أنسجة الكبد واصفرار الجلد والعينين )الصفراء(<br />&bull;بثور، قرح )شري( حكة وزيادة التعرق<br />&bull;شعور بالتعب وشعور عام بالإعياء وحمى<br />الأعراض الجانبية النادرة )قد تصيب شخصاً واحداً من كل 1,000 شخص(:<br />&bull;انخفاض المعدل الطبيعي لعدد كرات الدم البيضاء التي تقاوم العدوى، وخلايا الدم التي تساعد<br />في وقف النزيف<br />&bull;تغير لون الجلد إلى اللون الأحمر أو الأرجواني والذي ربما يعزي إلى نقص عدد الصفائح الدموية،<br />وتغيرات أخرى في خلايا الدم<br />&bull;تغيرات في كيمياء الدم )ارتفاع مستويات الكوليسترول والدهون في الدم(<br />&bull;انخفاض مستوى البوتاسيوم في الدم</p><p>الارتجاف<br />&bull;صورة غير طبيعية لمخطط كهربية القلب، تغير في معدل أو نظم ضربات القلب<br />&bull;فشل كبدي<br />&bull;تفاعلات حساسية )أحياناً تكون خطيرة( وتشمل الطفح الجلدي المتقيح الواسع الانتشار<br />وتقشر الجلد وتفاعلات خطيرة في الجلد وتورم الشفاه أو الوجه<br />&bull;تساقط الشعر<br />التردد غير معروف ، ولكن قد يحدث )لا يمكن تقديره من البيانات المتاحة(:<br />تفاعل فرط الحساسية مع الطفح الجلدي ، والحمى ، وتورم الغدد ، وزيادة في نوع من خلايا الدم البيضاء<br />)فرط الحمضات( والتهاب الأعضاء الداخلية )الكبد والرئتين والقلب والكليتين والأمعاء الغليظة(<br />))DRESS( )التفاعلات الدوائية أو الطفح الجلدي مع فرط الحمضات والأعراض الجهازية<br />إذا شعرت بأي أعراض جانبية فتحدث إلى طبيبك أو الصيدلي أو الممرضة، ويشمل هذا أي أعراض<br />جانبية محتملة غير واردة في هذه النشرة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>حفظ الدواء<br />&bull;يُحفط هذا الدواء بعيداً عن متناول الأطفال ومرمى نظرهم.<br />&bull;لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية الموضح على الشريط وعلى العبوة، يشير<br />تاريخ الصلاحية إلى اليوم الأخير من الشهر المذكور.<br />&bull;يُحفظ في درجة حرارة أقل من 30 درجة مئوية.<br />&bull;لا تلقِ أي أدوية في مياه الصرف أو في الفضلات المنزلية. سل الصيدلي عن طريقة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>محتويات كبسولات أوديكون 150 ملجم<br />&bull;المادة الفعالة هي الفلوكونازول.<br />&bull;تحتوي كل كبسولة جيلاتينية صلبة على فلوكونازول 150 ملجم.<br />&bull;المكونات الأخرى: اللاكتوز ونشا ذرة ولوريل سلفات الصوديوم وسيليكا غروانية لا مائية تلك نقي<br />&rdquo; وأغلفه كبسولات جيلاتينية صلبة مقاس &ldquo; 0<br />وثاني أكسيد )FD&amp;C Blue مكونات غلاف الكبسولة: جيلاتين ولون أزرق نيلي مائل إلى القرمزي ) 2<br />التيتانيوم</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>الشكل الصيدلاني لكبسولات أوديكون 150 ملجم؟<br />باللون الأسود، &rdquo;FL كبسولات جيلاتينية صلبة مقاس &ldquo; 0&rdquo; عليها غطاء فيروزي مطبوع عليه &ldquo; 150<br />وجسم فيروزي اللون، وممتلئة بمسحوق حبيبي أبيض مائل إلى الأصفر لا يحتوي على أي مادة غريبة<br />مرئية.<br />العبوة:<br />تأتي كبسولات أوديكون 150 مجم في عبوة بها شرائط.<br />عبوة تحتوي على كبسولة واحدة )شريط واحد(.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>نيوفارما<br />95 ,مدينه أبوظبي -89- قطعه رقم إيه- 1<br />الصناعيه، مصفح، ص. ب. 72900 . أبوظبى.إ.ع.م</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مارس 2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Odecon Capsules 150 mg
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each capsule contains fluconazole 150 mg, For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Capsule
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.1 Therapeutic indications<br />Odecon is indicated in the following fungal infections (see section 5.1). Odecon is indicated in adults for the treatment of:<br />&bull; Cryptococcal meningitis (see section 4.4).<br />&bull; Coccidioidomycosis (see section 4.4).<br />&bull; Invasive candidiasis.<br />&bull; Mucosal candidiasis including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis.<br />&bull; Chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient.<br />&bull; Vaginal candidiasis, acute or recurrent; when local therapy is not appropriate.<br />&bull; Candidal balanitis when local therapy is not appropriate.<br />&bull; Dermatomycosis including tinea pedis, tinea corporis, tinea cruris, tinea versicolor and dermal candida infections when systemic therapy is indicated.<br />&bull; Tinea unguinium (onychomycosis) when other agents are not considered appropriate.</p><p>Odecon is indicated in adults for the prophylaxis of:<br />&bull; Relapse of cryptococcal meningitis in patients with high risk of recurrence.<br />&bull; Relapse of oropharyngeal or oesophageal candidiasis in patients infected with HIV who are at high risk of experiencing relapse.<br />&bull; To reduce the incidence of recurrent vaginal candidiasis (4 or more episodes a year).<br />&bull; Prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving Hematopoietic Stem Cell Transplantation (see section 5.1)). Odecon is indicated in term newborn infants, infants, toddlers, children, and adolescents aged from 0 to 17 years old:<br />Odecon is used for the treatment of mucosal candidiasis (oropharyngeal, oesophageal), invasive candidiasis, cryptococcal meningitis and the prophylaxis of candidal infections in immunocompromised patients. Odecon can be used as maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of reoccurrence (see section 4.4).</p><p>Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly.<br />Consideration should be given to official guidance on the appropriate use of antifungals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />The dose should be based on the nature and severity of the fungal infection. Treatment of infections requiring multiple dosing should be continued until clinical parameters or laboratory tests indicate that active fungal infection has subsided. An inadequate period of treatment may lead to recurrence of active infection.</p><p>Adults Indications Posology Duration of treatment<br />Cryptococcosis<br />- Treatment of cryptococcal meningitis.<br />Loading dose: 400 mg on Day 1<br />Subsequent dose: 200 mg to 400 mg once daily<br />Usually at least 6 to 8 weeks.<br />In life threatening infections the daily dose can be increased to 800 mg<br />- Maintenance therapy to prevent relapse of cryptococcal meningitis in patients with high risk of recurrence.<br />200 mg once daily<br />Indefinitely at a daily dose of 200 mg<br />Coccidioidomycosis<br />200 mg to 400 mg once daily<br />11 months up to 24 months or longer depending on the patient. 800 mg daily may be considered for some infections and especially for meningeal disease<br />Invasive candidiasis<br />Loading dose: 800 mg on Day 1<br />Subsequent dose: 400 mg once daily<br />In general, the recommended duration of therapy for candidemia is for 2 weeks after first negative blood culture result and resolution of signs and symptoms attributable to candidemia.<br />Treatment of mucosal candidiasis<br />- Oropharyngeal candidiasis<br />Loading dose: 200 mg to 400 mg on Day 1<br />7 to 21 days (until oropharyngeal</p><p>Indications Posology Duration of treatment<br />Subsequent dose: 100 mg to 200 mg once daily<br />candidiasis is in remission).<br />Longer periods may be used in patients with severely compromised immune function<br />- Oesophageal candidiasis Loading dose: 200 mg to 400 mg on Day 1<br />Subsequent dose: 100 mg to 200 mg once daily<br />14 to 30 days (until oesophageal candidiasis is in remission).<br />Longer periods may be used in patients with severely compromised immune function<br />- Candiduria<br />200 mg to 400 mg once daily<br />7 to 21 days. Longer periods may be used in patients with severely compromised immune function.<br />- Chronic atrophic candidiasis<br />50 mg once daily<br />14 days<br />- Chronic mucocutaneous candidiasis<br />50 mg to 100 mg once daily<br />Up to 28 days. Longer periods depending on both the severity of infection or underlying immune compromisation and infection<br />Prevention of relapse of mucosal candidiasis in patients infected with HIV who are at high risk of experiencing relapse<br />- Oropharyngeal candidiasis<br />100 mg to 200 mg once daily or 200 mg 3 times per week<br />An indefinite period for patients with chronic immune suppression<br />- Oesophageal candidiasis<br />100 mg to 200 mg once daily or 200 mg 3 times per week<br />An indefinite period for patients with chronic immune suppression<br />Genital candidiasis<br />- Acute vaginal candidiasis<br />- Candidal balanitis<br />150 mg<br />Single dose</p><p>- Treatment and prophylaxis of recurrent vaginal candidiasis (4 or more episodes a year).<br />150 mg every third day for a total of 3 doses (day 1, 4, and 7) followed by 150 mg once weekly maintenance dose<br />Maintenance dose: 6 months.</p><p>Dermatomycosis<br />- tinea pedis,<br />- tinea corporis,<br />- tinea cruris,<br />- candida infections<br />150 mg once weekly or 50 mg once daily<br />2 to 4 weeks, tinea pedis may require treatment for up to 6 weeks - tinea versicolor<br />300 mg to 400 mg once weekly<br />1 to 3 weeks<br />50 mg once daily<br />2 to 4 weeks<br />- tinea unguium(onychomycosis)<br />150 mg once weekly<br />Treatment should be continued until infected nail is replaced (uninfected nail grows in). Regrowth of fingernails and toenails normally requires 3 to 6 months and 6 to 12 months, respectively. However, growth rates may vary widely in individuals, and by age. After successful treatment of long-term chronic infections, nails occasionally remain disfigured.<br />Prophylaxis of candidal infections in patients with prolonged neutropenia<br />200 mg to 400 mg once daily<br />Treatment should start several days before the anticipated onset of neutropenia and continue for 7 days after recovery from neutropenia after the neutrophil count rises above 1000 cells per mm3.</p><p>Special populations<br />Elderly<br />Dosage should be adjusted based on the renal function (see &ldquo;Renal impairment&rdquo;).<br />Renal impairment<br />Odecon is predominantly excreted in the urine as unchanged active substance. No adjustments in single dose therapy are necessary. In patients (including paediatric population) with impaired renal function who will receive multiple doses of fluconazole, an initial dose of 50 mg to 400 mg should&nbsp;be given, based on the recommended daily dose for the indication. After this initial loading dose, the daily dose (according to indication) should be based on the following table:<br />Creatinine clearance (ml/min)<br />Percent of recommended dose<br />&gt;50<br />100%<br />&le;50 (no haemodialysis)<br />50%<br />Haemodialysis<br />100% after each haemodialysis<br />Patients on haemodialysis should receive 100% of the recommended dose after each haemodialysis; on non-dialysis days, patients should receive a reduced dose according to their creatinine clearance.<br />Hepatic impairment<br />Limited data are available in patients with hepatic impairment, therefore fluconazole should be administered with caution to patients with liver dysfunction (see sections 4.4 and 4.8).</p><p>Paediatric population<br />A maximum dose of 400 mg daily should not be exceeded in paediatric population.<br />As with similar infections in adults, the duration of treatment is based on the clinical and mycological response. Odecon is administered as a single daily dose.<br />For paediatric patients with impaired renal function, see dosing in &ldquo;Renal impairment&rdquo;. The pharmacokinetics of fluconazole has not been studied in paediatric population with renal insufficiency (for &ldquo;Term newborn infants&rdquo; who often exhibit primarily renal immaturity please see below).<br />Infants, toddlers and children (from 28 days to 11 years old): Indication Posology Recommendations<br />- Mucosal candidiasis<br />Initial dose: 6 mg/kg<br />Subsequent dose: 3 mg/kg once daily<br />Initial dose may be used on the first day to achieve steady state levels more rapidly<br />- Invasive candidiasis<br />- Cryptococcal meningitis<br />Dose: 6 to 12 mg/kg once daily<br />Depending on the severity of the disease<br />- Maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of recurrence<br />Dose: 6 mg/kg once daily<br />Depending on the severity of the disease<br />- Prophylaxis of Candida in immunocompromised patients<br />Dose: 3 to 12 mg/kg once daily<br />Depending on the extent and duration of the induced neutropenia (see Adults posology)<br />Adolescents (from 12 to 17 years old):<br />Depending on the weight and pubertal development, the prescriber would need to assess which posology (adults or children) is the most appropriate. Clinical data indicate that children have a higher fluconazole clearance than observed for adults. A dose of 100, 200 and 400 mg in adults corresponds to a 3, 6 and 12 mg/kg dose in children to obtain a comparable systemic exposure.<br />Safety and efficacy for genital candidiasis indication in paediatric population has not been established. Current available safety data for other paediatric indications are described in section 4.8.</p><p>If treatment for genital candidiasis is imperative in adolescents (from 12 to 17 years old), the posology should be the same as adults posology.<br />Term newborn infants (0 to 27 days):<br />Neonates excrete fluconazole slowly. There are few pharmacokinetic data to support this posology in term newborn infants (see section 5.2).<br />Age group<br />Posology<br />Recommendations<br />Term newborn infants (0 to 14 days)<br />The same mg/kg dose as for infants, toddlers and children should be given every 72 hours<br />A maximum dose of 12 mg/kg every 72 hours should not be exceeded<br />Term newborn infants (from 15 to 27 days)<br />The same mg/kg dose as for infants, toddlers and children should be given every 48 hours<br />A maximum dose of 12 mg/kg every 48 hours should not be exceeded Method of administration<br />Odecon may be administered either orally (Capsules and Powder for Oral Suspension) or by intravenous infusion (Solution for Infusion), the route being dependent on the clinical state of the patient. On transferring from the intravenous to the oral route, or vice versa, there is no need to change the daily dose.<br />The physician should prescribe the most appropriate pharmaceutical form and strength according to age, weight and dose. The capsule formulation is not adapted for use in infants and small children. Oral liquid formulations of fluconazole are available that are more suitable in this population.<br />The capsules should be swallowed whole and independent of food intake</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4.3 Contraindications
Hypersensitivity to the active substance, to related azole substances, or to any of the excipients listed in section 6.1.
Coadministration of terfenadine is contraindicated in patients receiving Odecon at multiple doses of 400 mg per day or higher based upon results of a multiple dose interaction study. Coadministration of other medicinal products known to prolong the QT interval and which are metabolised via the cytochrome P450 (CYP) 3A4 such as cisapride, astemizole, pimozide, quinidine, and erythromycin are contraindicated in patients receiving fluconazole (see sections 4.4 and 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.4 Special warnings and precautions for use Tinea capitis<br />Fluconazole has been studied for treatment of tinea capitis in children. It was shown not to be superior to griseofulvin and the overall success rate was less than 20%. Therefore, Odecon should not be used for tinea capitis. Cryptococcosis<br />The evidence for efficacy of fluconazole in the treatment of cryptococcosis of other sites (e.g. pulmonary and cutaneous cryptococcosis) is limited, which prevents dosing recommendations&nbsp;Deep endemic mycoses<br />The evidence for efficacy of fluconazole in the treatment of other forms of endemic mycoses such as paracoccidioidomycosis, lymphocutaneous sporotrichosis and histoplasmosis is limited, which prevents specific dosing recommendations. Renal system<br />Odecon should be administered with caution to patients with renal dysfunction (see section 4.2). Adrenal insufficiency<br />Ketoconazole is known to cause adrenal insufficiency, and this could also although rarely seen be applicable to fluconazole. Adrenal insufficiency relating to concomitant treatment with prednisone, see section 4.5 &#39;The effect of fluconazole on other medicinal products&#39;. Hepatobiliary system<br />Odecon should be administered with caution to patients with liver dysfunction.<br />Odecon has been associated with rare cases of serious hepatic toxicity including fatalities, primarily in patients with serious underlying medical conditions. In cases of fluconazole associated hepatotoxicity, no obvious relationship to total daily dose, duration of therapy, sex or age of patient has been observed. Fluconazole hepatotoxicity has usually been reversible on discontinuation of therapy.<br />Patients who develop abnormal liver function tests during fluconazole therapy must be monitored closely for the development of more serious hepatic injury.<br />The patient should be informed of suggestive symptoms of serious hepatic effect (important asthenia, anorexia, persistent nausea, vomiting and jaundice). Treatment of fluconazole should be immediately discontinued and the patient should consult a physician. Cardiovascular system<br />Some azoles, including fluconazole, have been associated with prolongation of the QT interval on the electrocardiogram. Fluconazole causes QT prolongation via the inhibition of Rectifier Potassium Channel current (Ikr). The QT prolongation caused by other medicinal products (such as amiodarone) may be amplified via the inhibition of cytochrome P450 (CYP) 3A4. During post-marketing surveillance, there have been very rare cases of QT prolongation and torsades de pointes in patients taking Odecon. These reports included seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities and concomitant treatment that may have been contributory. Patients with hypokalaemia and advanced cardiac failure are at an increased risk for the occurrence of life threatening ventricular arrhythmias and torsades de pointes.<br />Odecon should be administered with caution to patients with potentially proarrhythmic conditions.<br />Coadministration of other medicinal products known to prolong the QT interval and which are metabolised via the cytochrome P450 (CYP) 3A4 are contraindicated (see sections 4.3 and 4.5). Halofantrine<br />Halofantrine has been shown to prolong QTc interval at the recommended therapeutic dose and is a substrate of CYP3A4. The concomitant use of fluconazole and halofantrine is therefore not recommended (see section 4.5).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.5 Interaction with other medicinal products and other forms of interaction Concomitant use of the following other medicinal products is contraindicated: Cisapride: There have been reports of cardiac events including torsades de pointes in patients to whom fluconazole and cisapride were coadministered. A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval. Concomitant treatment with fluconazole and cisapride is contraindicated (see section 4.3). Terfenadine: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole antifungals in conjunction with terfenadine, interaction studies have been performed. One study at a 200 mg daily dose of fluconazole failed to demonstrate a prolongation in QTc interval. Another study at a 400 mg and 800 mg daily dose of fluconazole demonstrated that fluconazole taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly. The combined use of fluconazole at doses of<br />PRODUCT ODECON CAPSULES 150 MG<br />MODULE - 1<br />400 mg or greater with terfenadine is contraindicated (see section 4.3). The coadministration of fluconazole at doses lower than 400 mg per day with terfenadine should be carefully monitored.</p><p>Astemizole: Concomitant administration of fluconazole with astemizole may decrease the clearance of astemizole. Resulting increased plasma concentrations of astemizole can lead to QT prolongation and rare occurrences of torsades de pointes. Coadministration of fluconazole and astemizole is contraindicated (see section 4.3). Pimozide: Although not studied in vitro or in vivo, concomitant administration of fluconazole with pimozide may result in inhibition of pimozide metabolism. Increased pimozide plasma concentrations can lead to QT prolongation and rare occurrences of torsades de pointes. Coadministration of fluconazole and pimozide is contraindicated (see section 4.3). Quinidine: Although not studied in vitro or in vivo, concomitant administration of fluconazole with quinidine may result in inhibition of quinidine metabolism. Use of quinidine has been associated with QT prolongation and rare occurrences of torsades de pointes. Coadministration of fluconazole and quinidine is contraindicated (see section 4.3). Erythromycin: Concomitant use of fluconazole and erythromycin has the potential to increase the risk of cardiotoxicity (prolonged QT interval, torsades de pointes) and consequently sudden heart death. Coadministration of fluconazole and erythromycin is contraindicated (see section 4.3). Concomitant use of the following other medicinal products cannot be recommended: Halofantrine: Fluconazole can increase halofantrine plasma concentration due to an inhibitory effect on CYP3A4. Concomitant use of fluconazole and halofantrine has the potential to increase the risk of cardiotoxicity (prolonged QT interval, torsades de pointes) and consequently sudden heart death. This combination should be avoided (see section 4.4). Concomitant use that should be used with caution&nbsp;Amiodarone: Concomitant administration of fluconazole with amiodarone may increase QT prolongation. Caution must be exercised if the concomitant use of fluconazole and amiodarone is necessary, notably with high dose fluconazole (800 mg). Concomitant use of the following other medicinal products lead to precautions and dose adjustments: The effect of other medicinal products on fluconazole Rifampicin: Concomitant administration of fluconazole and rifampicin resulted in a 25% decrease in the AUC and a 20% shorter half-life of fluconazole. In patients receiving concomitant rifampicin, an increase of the fluconazole dose should be considered.<br />Interaction studies have shown that when oral fluconazole is coadministered with food, cimetidine, antacids or following total body irradiation for bone marrow transplantation, no clinically significant impairment of fluconazole absorption occurs.</p><p>Hydrochlorothiazide: In a pharmacokinetic interaction study, coadministration of multiple-dose hydrochlorothiazide to healthy volunteers receiving fluconazole increased plasma concentration of fluconazole by 40%. An effect of this magnitude should not necessitate a change in the fluconazole dose regimen in subjects receiving concomitant diuretics. The effect of fluconazole on other medicinal products<br />Fluconazole is a moderate inhibitor of cytochrome P450 (CYP) isoenzymes 2C9 and 3A4. Fluconazole is also a strong inhibitor of the isozyme CYP2C19. In addition to the observed/documented interactions mentioned below, there is a risk of increased plasma concentration of other compounds metabolised by CYP2C9, CYP2C19 and CYP3A4 coadministered with fluconazole. Therefore, caution should be exercised when using these combinations and the patients should be carefully monitored. The enzyme inhibiting effect of fluconazole persists 4-5 days after discontinuation of fluconazole treatment due to the long half-life of fluconazole (see section 4.3). Alfentanil: During concomitant treatment with fluconazole (400 mg) and intravenous alfentanil (20 &mu;g/kg) in healthy volunteers the alfentanil AUC 10 increased 2-fold, probably through inhibition of CYP3A4. Dose adjustment of alfentanil may be necessary. Amitriptyline, nortriptyline: Fluconazole increases the effect of amitriptyline and nortriptyline. 5-nortriptyline and/or S-amitriptyline may be measured at initiation of the combination therapy and after one week. Dose of amitriptyline/nortriptyline should be adjusted, if necessary Amphotericin B: Concurrent administration of fluconazole and amphotericin B in infected normal and immunosuppressed mice showed the following results: a small additive antifungal effect in systemic infection with C. albicans, no interaction in intracranial infection with Cryptococcus neoformans, and antagonism of the two medicinal products in systemic infection with Aspergillus fumigatus. The clinical significance of results obtained in these studies is unknown. Anticoagulants: In post-marketing experience, as with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, haematuria, and melena) have been reported, in association with increases in prothrombin time in patients receiving fluconazole concurrently with warfarin. During concomitant treatment with fluconazole and warfarin the prothrombin time was prolonged up to 2-fold, probably due to an inhibition of the warfarin metabolism through CYP2C9. In patients receiving coumarin-type or indanedione anticoagulants concurrently with fluconazole the prothrombin time should be carefully monitored. Dose adjustment of the anticoagulant may be necessary. Benzodiazepines (short acting), i.e. midazolam, triazolam: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. Concomitant intake of fluconazole 200 mg and midazolam 7.5 mg orally increased the midazolam AUC and half-life 3.7-fold and 2.2-fold, respectively. Fluconazole 200 mg daily given concurrently with triazolam 0.25 mg orally increased the triazolam AUC and half-life 4.4-fold and 2.3-fold, respectively. Potentiated and prolonged effects of triazolam have been observed at concomitant treatment with fluconazole. If concomitant benzodiazepine therapy is necessary in&nbsp;benzodiazepine dose, and the patients should be appropriately monitored. Carbamazepine: Fluconazole inhibits the metabolism of carbamazepine and an increase in serum carbamazepine of 30% has been observed. There is a risk of developing carbamazepine toxicity. Dose adjustment of carbamazepine may be necessary depending on concentration measurements/effect. Calcium channel blockers: Certain calcium channel antagonists (nifedipine, nicardipine, amlodipine, verapamil and felodipine) are metabolised by CYP3A4. Fluconazole has the potential to increase the systemic exposure of the calcium channel antagonists. Frequent monitoring for adverse events is recommended. Celecoxib: During concomitant treatment with fluconazole (200 mg daily) and celecoxib (200 mg) the celecoxib Cmax and AUC increased by 68% and 134%, respectively. Half of the celecoxib dose may be necessary when combined with fluconazole. Cyclophosphamide: Combination therapy with cyclophosphamide and fluconazole results in an increase in serum bilirubin and serum creatinine. The combination may be used while taking increased consideration to the risk of increased serum bilirubin and serum creatinine. Fentanyl: One fatal case of fentanyl intoxication due to possible fentanyl fluconazole interaction was reported. Furthermore, it was shown in healthy volunteers that fluconazole delayed the elimination of fentanyl significantly. Elevated fentanyl concentration may lead to respiratory depression. Patients should be monitored closely for the potential risk of respiratory depression. Dosage adjustment of fentanyl may be necessary. HMG CoA reductase inhibitors: The risk of myopathy and rhabdomyolysis increases when fluconazole is coadministered with HMG-CoA reductase inhibitors metabolised through CYP3A4, such as atorvastatin and simvastatin, or through CYP2C9, such as fluvastatin. If concomitant therapy is necessary, the patient should be observed for symptoms of myopathy and rhabdomyolysis and creatine kinase should be monitored. HMG-CoA reductase inhibitors should be discontinued if a marked increase in creatine kinase is observed or myopathy/rhabdomyolysis is diagnosed or suspected. Olaparib: Moderate inhibitors of CYP3A4 such as fluconazole increase olaparib plasma concentrations; concomitant use is not recommended. If the combination cannot be avoided, limit the dose of olaparib to 200 mg twice daily. Immunosuppresors (i.e. ciclosporin, everolimus, sirolimus and tacrolimus): Ciclosporin: Fluconazole significantly increases the concentration and AUC of ciclosporin. During concomitant treatment with fluconazole 200 mg daily and ciclosporin (2.7 mg/kg/day) there was a 1.8-fold increase in ciclosporin AUC. This combination may be used by reducing the dose of ciclosporin depending on ciclosporin concentration.</p><p>Everolimus: Although not studied in vivo or in vitro, fluconazole may increase serum concentrations of everolimus through inhibition of CYP3A4. Sirolimus: Fluconazole increases plasma concentrations of sirolimus presumably by inhibiting the metabolism of sirolimus via CYP3A4 and P-glycoprotein. This combination may be used with a dose adjustment of sirolimus depending on the effect/concentration measurements. Tacrolimus: Fluconazole may increase the serum concentrations of orally administered tacrolimus up to 5 times due to inhibition of tacrolimus metabolism through CYP3A4 in the intestines. No significant pharmacokinetic changes have been observed when tacrolimus is given intravenously. Increased tacrolimus levels have been associated with nephrotoxicity. Dose of orally administered tacrolimus should be decreased depending on tacrolimus concentration. Losartan: Fluconazole inhibits the metabolism of losartan to its active metabolite (E-31 74) which is responsible for most of the angiotensin II-receptor antagonism which occurs during treatment with losartan. Patients should have their blood pressure monitored continuously. Methadone: Fluconazole may enhance the serum concentration of methadone. Dose adjustment of methadone may be necessary. Non-steroidal anti-inflammatory drugs: The Cmax and AUC of flurbiprofen was increased by 23% and 81%, respectively, when coadministered with fluconazole compared to administration of flurbiprofen alone. Similarly, the Cmax and AUC of the pharmacologically active isomer [S-(+)-ibuprofen] was increased by 15% and 82%, respectively, when fluconazole was coadministered with racemic ibuprofen (400 mg) compared to administration of racemic ibuprofen alone.<br />Although not specifically studied, fluconazole has the potential to increase the systemic exposure of other NSAIDs that are metabolised by CYP2C9 (e.g. naproxen, lornoxicam, meloxicam, diclofenac). Frequent monitoring for adverse events and toxicity related to NSAIDs is recommended. Adjustment of dose of NSAIDs may be needed. Phenytoin: Fluconazole inhibits the hepatic metabolism of phenytoin. Concomitant repeated administration of 200 mg fluconazole and 250 mg phenytoin intravenously, caused an increase of the phenytoin AUC24 by 75% and Cmin by 128%. With coadministration, serum phenytoin concentration levels should be monitored in order to avoid phenytoin toxicity. Prednisone: There was a case report that a liver-transplanted patient treated with prednisone developed acute adrenal cortex insufficiency when a three month therapy with fluconazole was discontinued. The discontinuation of fluconazole presumably caused an enhanced CYP3A4 activity which led to increased metabolism of prednisone. Patients on long-term treatment with fluconazole and prednisone should be carefully monitored for adrenal cortex insufficiency when fluconazole is discontinued.</p><p>Rifabutin: Fluconazole increases serum concentrations of rifabutin, leading to increase in the AUC of rifabutin up to 80%. There have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered. In combination therapy, symptoms of rifabutin toxicity should be taken into consideration. Saquinavir: Fluconazole increases the AUC and Cmax of saquinavir with approximately 50% and 55% respectively, due to inhibition of saquinavir&#39;s hepatic metabolism by CYP3A4 and inhibition of P-glycoprotein. Interaction with saquinavir/ritonavir has not been studied and might be more marked. Dose adjustment of saquinavir may be necessary. Sulfonylureas: Fluconazole has been shown to prolong the serum half-life of concomitantly administered oral sulfonylureas (e.g., chlorpropamide, glibenclamide, glipizide, tolbutamide) in healthy volunteers. Frequent monitoring of blood glucose and appropriate reduction of sulfonylurea dose is recommended during coadministration. Theophylline: In a placebo controlled interaction study, the administration of fluconazole 200 mg for 14 days resulted in an 18% decrease in the mean plasma clearance rate of theophylline. Patients who are receiving high dose theophylline or who are otherwise at increased risk for theophylline toxicity should be observed for signs of theophylline toxicity while receiving fluconazole. Therapy should be modified if signs of toxicity develop. Tofacitinib: Exposure of tofacitinib is increased when tofacitinib is co-administered with medications that result in both moderate inhibition of CYP3A4 and strong inhibition of CYP2C19 (e.g., fluconazole). Therefore, it is recommended to reduce tofacitinib dose to 5 mg once daily when it is combined with these drugs. Vinca alkaloids: Although not studied, fluconazole may increase the plasma levels of the vinca alkaloids (e.g. vincristine and vinblastine) and lead to neurotoxicity, which is possibly due to an inhibitory effect on CYP3A4. Vitamin A: Based on a case-report in one patient receiving combination therapy with all-trans-retinoid acid (an acid form of vitamin A) and fluconazole, CNS related undesirable effects have developed in the form of pseudotumour cerebri, which disappeared after discontinuation of fluconazole treatment. This combination may be used but the incidence of CNS related undesirable effects should be borne in mind. Voriconazole: (CYP2C9, CYP2C19 and CYP3A4 inhibitor): Coadministration of oral voriconazole (400 mg Q12h for 1 day, then 200 mg Q12h for 2.5 days) and oral fluconazole (400 mg on day 1, then 200 mg Q24h for 4 days) to 8 healthy male subjects resulted in an increase in Cmax and AUC of voriconazole by an average of 57% (90% CI: 20%, 107%) and 79% (90% CI: 40%, 128%), respectively. The reduced dose and/or frequency of voriconazole and fluconazole that would eliminate this effect have not been established. Monitoring for voriconazole associated adverse events is recommended if voriconazole is used sequentially after fluconazole<br />Zidovudine: Fluconazole increases Cmax and AUC of zidovudine by 84% and 74%, respectively, due to an approx. 45% decrease in oral zidovudine clearance. The half-life of zidovudine was likewise prolonged by approximately 128% following combination therapy with fluconazole. Patients receiving this combination should be monitored for the development of zidovudine-related adverse reactions. Dose reduction of zidovudine may be considered. Azithromycin: An open-label, randomized, three-way crossover study in 18 healthy subjects assessed the effect of a single 1200 mg oral dose of azithromycin on the pharmacokinetics of a single 800 mg oral dose of fluconazole as well as the effects of fluconazole on the pharmacokinetics of azithromycin. There was no significant pharmacokinetic interaction between fluconazole and azithromycin. Oral contraceptives: Two pharmacokinetic studies with a combined oral contraceptive have been performed using multiple doses of fluconazole. There were no relevant effects on hormone level in the 50 mg fluconazole study, while at 200 mg daily, the AUCs of ethinyl estradiol and levonorgestrel were increased 40% and 24%, respectively. Thus, multiple dose use of fluconazole at these doses is unlikely to have an effect on the efficacy of the combined oral contraceptive. Ivacaftor: Co-administration with ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, increased ivacaftor exposure by 3-fold and hydroxymethyl-ivacaftor (M1) exposure by 1.9-fold. A reduction of the ivacaftor dose to 150 mg once daily is recommended for patients taking concomitant moderate CYP3A inhibitors, such as fluconazole and erythromycin.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.6 Fertility, pregnancy and lactation Pregnancy<br />An observational study has suggested an increased risk of spontaneous abortion in women treated with fluconazole during the first trimester.<br />There have been reports of multiple congenital abnormalities (including brachycephalia, ears dysplasia, giant anterior fontanelle, femoral bowing and radio-humeral synostosis) in infants whose mothers were treated for at least three or more months with high doses (400 - 800 mg daily) of fluconazole for coccidioidomycosis. The relationship between fluconazole use and these events is unclear.<br />Studies in animals have shown reproductive toxicity (see section 5.3).<br />Fluconazole in standard doses and short-term treatments should not be used in pregnancy unless clearly necessary.<br />Fluconazole in high dose and/or in prolonged regimens should not be used during pregnancy except for potentially life-threatening infections. Breast-feeding<br />Fluconazole passes into breast milk to reach concentrations similar to those in plasma (see section 5.2). Breast-feeding may be maintained after a single dose of 150 mg fluconazole. Breast-feeding is not recommended after repeated use or after high dose fluconazole. The developmental and health benefits of breast-feeding should be considered along with the mother&#39;s clinical need for Odecon and&nbsp;any potential adverse effects on the breast-fed child from Odecon or from the underlying maternal condition. Fertility<br />Fluconazole did not affect the fertility of male or female rats (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies have been performed on the effects of Odecon on the ability to drive or use machines.<br />Patients should be warned about the potential for dizziness or seizures (see section 4.8) while taking Odecon and should be advised not to drive or operate machines if any of these symptoms occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most frequently (&gt;1/10) reported adverse reactions are headache, abdominal pain, diarrhoea, nausea, vomiting, alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased and rash.<br />The following adverse reactions have been observed and reported during treatment with Odecon with the following frequencies: Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>System Organ Class<br />Common<br />Uncommon<br />Rare<br />Not Known<br />Blood and the lymphatic system disorders<br />Anaemia<br />Agranulocytosis, leukopenia, thrombocytopenia, neutropenia<br />Immune system disorders<br />Anaphylaxis<br />Metabolism and nutrition disorders<br />Decreased appetite<br />Hypercholesterolaemia, hypertriglyceridaemia, hypokalaemia<br />Psychiatric disorders<br />Somnolence, insomnia<br />Nervous system disorders<br />Headache<br />Silures, paraesthesia, dizziness, taste perversion<br />Tremor<br />Ear and labyrinth disorders<br />Vertigo<br />Cardiac disorders<br />Torsade de pointes (see section 4.4), QT</p><p>System Organ Class<br />Common<br />Uncommon<br />Rare<br />Not Known<br />prolongation (see section 4.4)<br />Gastrointestinal disorders<br />Abdominal pain, vomiting, diarrhoea, nausea<br />Constipation dyspepsia, flatulence, dry mouth<br />Hepatobiliary disorders<br />Alanine aminotransferase increased (see section 4.4), aspartate aminotransferase increased (see section 4.4), blood alkaline phosphatase increased (see section 4.4)<br />Cholestasis (see section 4.4), jaundice (see section 4.4), bilirubin increased (see section 4.4)<br />Hepatic failure (see section 4.4), hepatocellular necrosis (see section 4.4), hepatitis (see section 4.4), hepatocellular damage (see section 4.4)<br />Skin and subcutaneous tissue disorders<br />Rash (see section 4.4)<br />Drug eruption* (see section 4.4), urticaria (see section 4.4), pruritus, increased sweating<br />Toxic epidermal necrolysis, (see section 4.4), Stevens-Johnson syndrome (see section 4.4), acute generalised exanthematous-pustulosis (see section 4.4), dermatitis exfoliative, angioedema, face oedema, alopecia<br />Drug reaction with eosinophilia and systemic symptoms (DRESS)<br />Musculoskeletal and connective tissue disorders<br />Myalgia<br />General disorders and administration site conditions<br />Fatigue, malaise, asthenia, fever</p><p>* including Fixed Drug Eruption Paediatric population<br />The pattern and incidence of adverse reactions and laboratory abnormalities recorded during paediatric clinical trials, excluding the genital candidiasis indication, are comparable to those seen in adults.</p><p>Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via</p><p>4.9 Overdose<br />There have been reports of overdose with Odecon. Hallucination and paranoid behaviour have been concomitantly reported.<br />In the event of overdose, symptomatic treatment (with supportive measures and gastric lavage if necessary) may be adequate.<br />Fluconazole is largely excreted in the urine; forced volume diuresis would probably increase the elimination rate. A three-hour haemodialysis session decreases plasma levels by approximately 50%.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antimycotics for systemic use, triazole derivatives, ATC code: J02AC01.<br />Mechanism of action<br />Fluconazole is a triazole antifungal agent. Its primary mode of action is the inhibition of fungal cytochrome P-450-mediated 14 alpha-lanosterol demethylation, an essential step in fungal ergosterol biosynthesis. The accumulation of 14 alpha-methyl sterols correlates with the subsequent loss of ergosterol in the fungal cell membrane and may be responsible for the antifungal activity of fluconazole. Fluconazole has been shown to be more selective for fungal cytochrome P-450 enzymes than for various mammalian cytochrome P-450 enzyme systems.<br />Fluconazole 50 mg daily given up to 28 days has been shown not to effect testosterone plasma concentrations in males or steroid concentration in females of child-bearing age. Fluconazole 200 mg to 400 mg daily has no clinically significant effect on endogenous steroid levels or on ACTH stimulated response in healthy male volunteers. Interaction studies with antipyrine indicate that single or multiple doses of fluconazole 50 mg do not affect its metabolism.<br />Susceptibility in vitro:</p><p>In vitro, fluconazole displays antifungal activity against most clinically common Candida species (including C. albicans, C. parapsilosis, C. tropicalis). C. glabrata shows a wide range of susceptibility while C. krusei is resistant to fluconazole.<br />Fluconazole also exhibits activity in vitro against Cryptococcus neoformans and Cryptococcus. gattii as well as the endemic moulds Blastomyces dermatiditis, Coccidioides immitis, Histoplasma capsulatum and Paracoccidioides brasiliensis.<br />Pharmacokinetic/pharmacodynamic relationship<br />In animal studies, there is a correlation between MIC values and efficacy against experimental mycoses due to Candidaspp. In clinical studies, there is an almost 1:1 linear relationship between the AUC and the dose of fluconazole. There is also a direct though imperfect relationship between the AUC or dose and a successful clinical response of oral candidosis and to a lesser extent candidaemia to treatment. Similarly cure is less likely for infections caused by strains with a higher fluconazole MIC.<br />Mechanisms of resistance<br />Candida spp have developed a number of resistance mechanisms to azole antifungal agents. Fungal strains which have developed one or more of these resistance mechanisms are known to exhibit high minimum inhibitory concentrations (MICs) to fluconazole which impacts adversely efficacy in vivo and clinically.<br />There have been reports of superinfection with Candida species other than C. albicans, which are often inherently not susceptible to fluconazole (e.g. Candida krusei). Such cases may require alternative antifungal therapy.<br />Breakpoints (according to EUCAST)<br />Based on analyses of pharmacokinetic/pharmacodynamic (PK/PD) data, susceptibility in vitro and clinical response EUCAST-AFST (European Committee on Antimicrobial susceptibility Testing-subcommittee on Antifungal Susceptibility Testing) has determined breakpoints for fluconazole for Candida species (EUCAST Fluconazole rational document (2007)-version 2). These have been divided into non-species related breakpoints; which have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific species, and species related breakpoints for those species most frequently associated with human infection. These breakpoints are given in the table below:<br />Antifungal<br />Species-related breakpoints (S&le;/R&gt;)<br />Non-species related breakpointsA<br />S&le;/R&gt;<br />Candida albicans<br />Candida glabrata<br />Candida krusei<br />Candida parapsilosis<br />Candida tropicalis<br />Fluconazole<br />2/4<br />IE<br />--<br />2/4<br />2/4<br />2/4</p><p>S = Susceptible, R = Resistant<br />A = Non-species related breakpoints have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific species. They are for use only for organisms that do not have specific breakpoints.<br />-- = Susceptibility testing not recommended as the species is a poor target for therapy with the medicinal product.<br />IE = There is insufficient evidence that the species in question is a good target for therapy with the medicinal product.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5.2 Pharmacokinetic properties<br />The pharmacokinetic properties of fluconazole are similar following administration by the intravenous or oral route.<br />Absorption<br />After oral administration fluconazole is well absorbed, and plasma levels (and systemic bioavailability) are over 90% of the levels achieved after intravenous administration. Oral absorption is not affected by concomitant food intake. Peak plasma concentrations in the fasting state occur between 0.5 and 1.5 hours post-dose. Plasma concentrations are proportional to dose. Ninety percent steady state levels are reached by day 4-5 with multiple once daily dosing. Administration of a loading dose (on day 1) of twice the usual daily dose enables plasma levels to approximate to 90% steady-state levels by day 2.<br />Distribution<br />The apparent volume of distribution approximates to total body water. Plasma protein binding is low (11-12%).<br />Fluconazole achieves good penetration in all body fluids studied. The levels of fluconazole in saliva and sputum are similar to plasma levels. In patients with fungal meningitis, fluconazole levels in the CSF are approximately 80% the corresponding plasma levels.<br />High skin concentration of fluconazole, above serum concentrations, are achieved in the stratum corneum, epidermis-dermis and eccrine sweat. Fluconazole accumulates in the stratum corneum. At a dose of 50 mg once daily, the concentration of fluconazole after 12 days was 73 &mu;g/g and 7 days after cessation of treatment the concentration was still 5.8 &mu;g/g. At the 150 mg once-a-week dose, the concentration of fluconazole in stratum corneum on day 7 was 23.4 &mu;g/g and 7 days after the second dose was still 7.1 &mu;g/g.<br />Concentration of fluconazole in nails after 4 months of 150 mg once-a-week dosing was 4.05 &mu;g/g in healthy and 1.8 &mu;g/g in diseased nails; and, fluconazole was still measurable in nail samples 6 months after the end of therapy.<br />Biotransformation<br />Fluconazole is metabolised only to a minor extent. Of a radioactive dose, only 11% is excreted in a changed form in the urine. Fluconazole is a moderate inhibitor of the isozymes CYP2C9 and CYP3A4 (see section 4.5). Fluconazole is also a strong inhibitor of the isozyme CYP2C19.</p><p>Elimination<br />Plasma elimination half-life for fluconazole is approximately 30 hours. The major route of excretion is renal, with approximately 80% of the administered dose appearing in the urine as unchanged medicinal product. Fluconazole clearance is proportional to creatinine clearance. There is no evidence of circulating metabolites.<br />The long plasma elimination half-life provides the basis for single dose therapy for vaginal candidiasis, once daily and once weekly dosing for other indications.<br />Pharmacokinetics in renal impairment<br />In patients with severe renal insufficiency, (GFR&lt; 20 ml/min) half life increased from 30 to 98 hours. Consequently, reduction of the dose is needed. Fluconazole is removed by haemodialysis and to a lesser extent by peritoneal dialysis. After three hours of haemodialysis session, around 50% of fluconazole is eliminated from blood.<br />Pharmacokinetics during lactation<br />A pharmacokinetic study in ten lactating women, who had temporarily or permanently stopped breast-feeding their infants, evaluated fluconazole concentrations in plasma and breast milk for 48 hours following a single 150 mg dose of Odecon. Fluconazole was detected in breast milk at an average concentration of approximately 98% of those in maternal plasma. The mean peak breast milk concentration was 2.61 mg/L at 5.2 hours post-dose. The estimated daily infant dose of fluconazole from breast milk (assuming mean milk consumption of 150 ml/kg/day) based on the mean peak milk concentration is 0.39 mg/kg/day, which is approximately 40% of the recommended neonatal dose (&lt;2 weeks of age) or 13% of the recommended infant dose for mucosal candidiasis.<br />Pharmacokinetics in children<br />Pharmacokinetic data were assessed for 113 paediatric patients from 5 studies; 2 single-dose studies, 2 multiple-dose studies, and a study in premature neonates. Data from one study were not interpretable due to changes in formulation pathway through the study. Additional data were available from a compassionate use study.<br />After administration of 2-8 mg/kg fluconazole to children between the ages of 9 months to 15 years, an AUC of about 38 &mu;g&middot;h/ml was found per 1 mg/kg dose units. The average fluconazole plasma elimination half-life varied between 15 and 18 hours and the distribution volume was approximately 880 ml/kg after multiple doses. A higher fluconazole plasma elimination half-life of approximately 24 hours was found after a single dose. This is comparable with the fluconazole plasma elimination half-life after a single administration of 3 mg/kg i.v. to children of 11 days-11 months old. The distribution volume in this age group was about 950 ml/kg.<br />Experience with fluconazole in neonates is limited to pharmacokinetic studies in premature newborns. The mean age at first dose was 24 hours (range 9-36 hours) and mean birth weight was 0.9 kg (range 0.75-1.10 kg) for 12 pre-term neonates of average gestation around 28 weeks. Seven patients completed the protocol; a maximum of five 6 mg/kg intravenous infusions of fluconazole were administered every 72 hours. The mean half-life (hours) was 74 (range 44-185) on day 1 which decreased, with time to a mean of 53 (range 30-131) on day 7 and 47 (range 27-68) on day 13. The area under the curve (microgram.h/ml) was 271 (range 173-385) on day 1 and increased with a mean&nbsp;of 490 (range 292-734) on day 7 and decreased with a mean of 360 (range 167-566) on day 13. The&nbsp;volume of distribution (ml/kg) was 1183 (range 1070-1470) on day 1 and increased, with time, to a mean of 1184 (range 510-2130) on day 7 and 1328 (range 1040-1680) on day 13.<br />Pharmacokinetics in elderly<br />A pharmacokinetic study was conducted in 22 subjects, 65 years of age or older receiving a single 50 mg oral dose of fluconazole. Ten of these patients were concomitantly receiving diuretics. The Cmax was 1.54 &mu;g/ml and occurred at 1.3 hours post-dose. The mean AUC was 76.4 &plusmn; 20.3 &mu;g&middot;h/ml, and the mean terminal half-life was 46.2 hours. These pharmacokinetic parameter values are higher than analogous values reported for normal young male volunteers. Coadministration of diuretics did not significantly alter AUC or Cmax. In addition, creatinine clearance (74 ml/min), the percent of medicinal product recovered unchanged in urine (0-24 h, 22%) and the fluconazole renal clearance estimates (0.124 ml/min/kg) for the elderly were generally lower than those of younger volunteers. Thus, the alteration of fluconazole disposition in the elderly appears to be related to reduced renal function characteristics of this group.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5.3 Preclinical safety data<br />Effects in non-clinical studies were observed only at exposures considered sufficiently in excess of the human exposure indicating little relevance to clinical use.<br />Carcinogenesis<br />Fluconazole showed no evidence of carcinogenic potential in mice and rats treated orally for 24 months at doses of 2.5, 5, or 10 mg/kg/day (approximately 2-7 times the recommended human dose). Male rats treated with 5 and 10 mg/kg/day had an increased incidence of hepatocellular adenomas.<br />Mutagenesis<br />Fluconazole, with or without metabolic activation, was negative in tests for mutagenicity in 4 strains of Salmonella typhimurium, and in the mouse lymphoma L5178Y system. Cytogenetic studies in vivo (murine bone marrow cells, following oral administration of fluconazole) and in vitro (human lymphocytes exposed to fluconazole at 1000 &mu;g/ml) showed no evidence of chromosomal mutations.<br />Reproductive toxicity<br />Fluconazole did not affect the fertility of male or female rats treated orally with daily doses of 5, 10, or 20 mg/kg or with parenteral doses of 5, 25, or 75 mg/kg.<br />There were no foetal effects at 5 or 10 mg/kg; increases in foetal anatomical variants (supernumerary ribs, renal pelvis dilation) and delays in ossification were observed at 25 and 50 mg/kg and higher doses. At doses ranging from 80 mg/kg to 320 mg/kg embryolethality in rats was increased and foetal abnormalities included wavy ribs, cleft palate, and abnormal cranio-facial ossification.<br />The onset of parturition was slightly delayed at 20 mg/kg orally and dystocia and prolongation of parturition were observed in a few dams at 20 mg/kg and 40 mg/kg intravenously. The disturbances in parturition were reflected by a slight increase in the number of still-born pups and decrease of neonatal survival at these dose levels. These effects on parturition are consistent with the species&nbsp;specific oestrogen-lowering property produced by high doses of fluconazole. Such a hormone change has not been observed in women treated with fluconazole (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>6.1 List of excipients<br />S. No<br />Material Name<br />Function<br />1.<br />Lactose Ph. Eur. (Pharmatose 200 M)<br />Diluent<br />2.<br />Maize Starch Ph. Eur.<br />Diluent &amp; binder<br />3.<br />Sodium Lauryl Sulphate BP<br />Dissolution enhancer<br />4.<br />Colloidal Anhydrous Silica BP/Ph. Eur.<br />Glidant<br />5.<br />Purified Talc Ph. Eur.<br />Lubricant<br />6.<br />Hard Gelatin Capsule Shells, Size &lsquo;0&rsquo;<br />Capsule shell</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The capsules are packed in Alu/Alu blisters and placed in a printed carton along with a pack<br />insert. Pack size: 1&rsquo;s (1&rsquo;s blister x 1)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Neopharma,
Plot No, A1 89-95, Industrial City of Abu Dhabi,
Mussafah, P.O. Box: 72900
Abu Dhabi, UAE.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                03/2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>